Singapore markets closed

Coherus BioSciences, Inc. (CHRS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.2300-0.1800 (-7.47%)
At close: 04:00PM EDT
2.2294 -0.00 (-0.03%)
After hours: 07:03PM EDT

Coherus BioSciences, Inc.

333 Twin Dolphin Drive
Suite 600
Redwood City, CA 94065
United States
650 649 3530

Full-time employees306

Key executives

NameTitlePayExercisedYear born
Mr. Dennis M. LanfearChairman, President & CEO1.79MN/A1955
Mr. Bryan J. McMichaelInterim CFO, Principal Financial and Accounting Officer, SVP-Accounting & Corporate ControllerN/AN/A1978
Mr. Richard L. HameisterChief Technical OfficerN/AN/AN/A
Ms. Jami TaylorVice President of Investor RelationsN/AN/AN/A
Cheston TurbyfillVice President of CommunicationsN/AN/AN/A
Mr. Scott SaywellExecutive Vice President of Corporate DevelopmentN/AN/AN/A
Ms. Rebecca SunshineChief Human Resources OfficerN/AN/A1963
Mr. Michael ChenSenior Vice President of Commercial Analytics & TradeN/AN/AN/A
Mr. Paul ReiderChief Commercial OfficerN/AN/A1969
Dr. Theresa M. Lavallee Ph.D.Chief Development Officer & Chairman of Scientific Advisory BoardN/AN/A1966
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Corporate governance

Coherus BioSciences, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.